Ten patients with refractory (n ‫؍‬ 8) or early relapsing (n ‫؍‬ 2) aggressive non-Hodgkin's lymphoma were enrolled in a pilot study evaluating a high-dose sequential chemotherapy regimen with peripheral blood stem cell (PBSC) support. Five treatment phases were scheduled: phase I (cyclophosphamide ؉ etoposide followed by lenograstim (G-CSF), and a PBSC harvest); phase II (cisplatinum ؉ cytarabine ؉ etoposide followed by lenograstim); phases III and IV (cyclophosphamide ؉ cytarabine ؉ etoposide followed by autologous PBSC infusion and lenograstim); and phase V (carmustine ؉ cytarabine ؉ etoposide ؉ melphalan followed by autologous PBSC infusion and lenograstim). Ten, nine, eight, six and four of the 10 patients received one, two, three, four and five of the five scheduled phases of treatment, respectively. Four patients were withdrawn from the study due to progressive disease and two due to thrombotic microangiopathy (TM). Moreover, in the four patients who completed all treatment phases, an additional case of TM was seen. In all three patients with TM, laboratory studies showed evidence of Coombs negative hemolytic anemia, thrombocytopenia, renal dysfunction and in addition cardiac failure in two patients. TM may be a new dose-limiting toxicity of high-dose sequential chemotherapy followed by repeated PBSC transplantation. Bone Marrow Transplantation (2001) 27, 531-536.
is administered. 3 Treatment with repeated courses of HDC, each followed by peripheral blood stem cell (PBSC) infusion, has recently been tested in various malignancies. Several phase II trials have demonstrated the feasibility of this approach in first-line therapy with moderately escalated chemotherapy doses without unexpected toxicity, in poor prognosis cancer patients. [4] [5] [6] [7] [8] [9] Given the low probability of cure in refractory or early relapsed aggressive NHL, we conducted a pilot study of sequential HDC consisting of high-dose alkylating agents, cytarabine and etoposide, which are the most effective drugs used in second-line salvage therapies and are also widely used in high-dose conditioning regimens in NHL. We report a high incidence of extra-hematological toxicity, and particularly of thrombotic microangiopathy (TM) with this regimen which was also associated with a low probability of cure in refractory NHL.
TM is characterized by Coombs negative microangiopathic hemolytic anemia, fragmented red cells (schistocytosis), consumptive thrombocytopenia and dysfunction of various organs due to arteriolar and capillary microthrombi, but particularly renal dysfunction and neurological abnormalities. This syndrome, closely related to the hemolytic uremic syndrome, may be associated with various disorders including infection, auto-immune disease, pregnancy and hematopoietic stem cell transplantation. 10 Anecdotal cases of TM have previously been reported in patients treated with HDC and autologous stem cell rescue but the physiopathology seems to be specific for the highdose chemotherapy setting. This supposedly singular presentation is supported by a study which showed that the underlying mechanisms of HDC-related TM could be different from those recently described in classic TM, which seem to mainly include a deficient von Willebrand factorcleaving protease. 11 The previous observations and this report suggest that HDC may lead to early endothelial cell injury resulting in failure of various organs, an unusual occurrence in classic TM.
Patients and methods

Eligibility criteria
Patients with aggressive NHL according to the REAL classification 12 were eligible if they were refractory to stan-dard treatment or if they relapsed soon after anthracyclinebased first-line therapy. Patients who failed to achieve a complete remission (CR) or relapsed less than 6 months after the end of first-line therapy were considered to have refractory disease. Patients who relapsed between 6 and 18 months after the end of first-line therapy were considered to have relapsed early. Additional eligibility criteria included a performance status р2, adequate bone marrow function (neutrophils у1 ϫ 10 9 /l and platelets Ͼ100 ϫ 10 9 /l), total bilirubin р1.5 mg/dl, alanine transferase р2 ϫ N, creatinine р120 m/l and left ventricular ejection fraction Ͼ50%. The local Human Investigations Committee approved the study and informed consent was obtained from all patients in accordance with institutional procedures. After each phase, sustained hematological recovery (neutrophils Ͼ1 ϫ 10 9 /l and platelets Ͼ100 ϫ 10 9 /l) was required before starting the next phase.
PBSC harvest
PBSC were harvested after phase I and, when necessary, also after phase II. At the end of aplasia, the CD34 ϩ cell count was monitored daily in a morning peripheral blood sample by flow cytometry. Leukaphereses were not performed if blood CD34 ϩ cell levels had not reached 2 ϫ 10 4 /ml. The CD34 cell count was also verified in each daily leukapheresis product. The PBSC harvest was considered successful if the CD34 ϩ cell yield was greater than 6 ϫ 10 6 /kg in one to three leukaphereses. One-third of the PBSC collected were reinfused after phases III, IV and V, respectively.
Evaluation of toxicity and response
The pretreatment work-up consisted of a history and physical examination, a complete blood cell count, and a biochemical profile (lactate dehydrogenase, alkaline phosphatase, bilirubin, albumin and creatinine). All patients had a pretreatment CSF analysis, a bone marrow biopsy and a whole body CT scan. A similar evaluation was performed after phase II and at the end of therapy. Response was assessed using standard criteria. 13 Toxicity was graded according to National Cancer Institute criteria. 14 Treatment was to be discontinued at any time in the event of patient refusal, non-compliance, rapidly progressive disease, or life-threatening toxicity.
Results
Initial patient characteristics (Table 1)
Ten consecutive patients were enrolled in the study: eight had refractory NHL, including two patients with high-grade transformation of follicular lymphoma, one with mantle cell lymphoma, one with peripheral T cell lymphoma and four with diffuse large B cell lymphoma; the remaining two patients had early relapsing diffuse large B cell lymphoma. The median age was 49 years (range 45-59) and the median time from diagnosis of NHL to enrollment in the study was 9 months, range 6-23). All patients had previously been treated with CHOP or a CHOP-like regimen and four had received prior limited-field radiotherapy.
TM case reports
UPN 4 developed respiratory distress on day 7 of phase V. A chest X-ray revealed bilateral infiltrates and the bronchoalveolar lavage (BAL) showed macrophages (97%), lymphocytes (2%), eosinophils (1%) and siderophages (40%) that were devoid of pathogens. The patient was diagnosed as having pneumonitis with intra-alveolar hemorrhage. High-dose corticosteroids were administered together with nasal oxygen therapy and intensive platelet transfusions. Respiratory distress gradually resolved over the following week and the patient was discharged on day 30. During the 4 months after the last PBSC transplant, he remained asymptomatic but persistently thrombocytopenic with no evidence of recurrence. During the fifth month of follow-up the patient sustained cardiac failure associated with a rapid escalation of the serum creatinine (352 m/l) and LDH (4000 U/l; normal value Ͻ600 U/l) levels, Coombs negative hemolytic anemia with 2% of fragmented red cells on the peripheral blood smear and undetectable serum haptoglobin (Ͻ0.05 g/l). TM was diagnosed and plasma transfusions were administered. TM gradually resolved but mild renal and cardiac failure requiring drug therapy persisted. UPN 7 had an uneventful transplant course after phase III. On day 32, the platelet count dropped to below 20 ϫ 10 9 /l with no evidence of disseminated intravascular coagulation (DIC) while the serum creatinine peaked at 198 m/l. Laboratory findings confirmed the diagnosis of TM: Coombs negative hemolytic anemia, 2% fragmented red cells on the peripheral blood smear, undetectable serum haptoglobin (Ͻ0.05 g/l) and elevated LDH (660 U/l). A kidney biopsy confirmed the diagnosis of TM. TM improved with steroids but the patient died 3 months later of disease progression. UPN 10 developed dyspnoea and hypoxia but was afebrile on day 9 of phase IV of the treatment. Chest X-ray showed bilateral interstitial infiltrates. BAL revealed macrophages (94%), lymphocytes (6%), eosinophils (2%) and less than 5% siderophages, but no pathogens. Highdose corticosteroids were administered with broad-spectrum antibiotics and the dyspnoea resolved gradually. On day 24, whereas leukocyte counts were normal, platelet counts dropped to below 20 ϫ 10 9 /l with no evidence of DIC. Laboratory evaluation revealed 2.8% fragmented red cells on the peripheral blood smear, a serum creatinine of 270 m/l, undetectable serum haptoglobin (Ͻ0.05 g/l) and LDH of 1928 U/l. The patient was diagnosed as having TM. High-dose corticosteroids and plasma transfusion did not obviate terminal chronic renal insufficiency requiring hemodialysis. Moreover, this patient had sustained cardiac failure within the first week of TM which responded moderately to treatment. Following a relapse of the lymphoma 10 months later, the patient died 12 months post transplantation.
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Other toxicities
The median time to у0.5 ϫ 10 9 /l neutrophils was 12 days (range 9-15) after phase I and 12 (range 9-14) after phase II. The median time to platelet count у20 ϫ 10 9 /l that was not dependent on transfusion was 12 days (range 8-13) after phase I and 12 days (range 9-14) after phase II. After phases III and IV, the median time to у0.5 ϫ 10 9 /l neutrophils was 15 days (range 10-22) and the median time to a platelet count у20 ϫ 10 9 /l that was not transfusion dependent was 13 days (range 10-23). Phase IV was administered at a median time interval of 76 days (range 72-83; planned time interval: day 72) from the initiation of therapy. Phase V was started after a median interval of 118 days (range 107-121; planned time interval: day 102). After phase V, the median time to neutrophil recovery was 14 days (range 10-16) and the median time to platelet recovery was 13 days (range [11] [12] [13] [14] [15] [16] [17] [18] .
Grade III mucositis was observed in one patient after phase I but not after phase II. Febrile neutropenia occurred in 90% of the patients after phases I and II. After phases III, IV and V, grade III mucositis occurred in 12%, 0% and 25% of the patients, respectively. Febrile neutropenic episodes occurred in all patients after phases III, IV and V. Major toxicity was seen in four patients, including the three patients who experienced thrombotic microangiopathy (TM) and one patient with fatal pneumonitis.
Outcome (Table 2)
The PBSC harvest was considered successful in eight patients (80%) after the first collection of PBSC (phase I): median 15 (8-25) ϫ 10 6 CD34 ϩ cells/kg. Successful harvest criteria were fulfilled by one of the two remaining patients after the second collection of PBSC during phase II, and the last patient was withdrawn from the study after phase I due to progressive disease.
Two patients were withdrawn from the study after phase II due to disease progression (UPN 1 and 9) and eight were responders (five CR and three PR) and received at least one course of HDC with PBSC transplantation. In this group, four patients did not complete the entire course of therapy due to early disease progression, after phases III and IV, respectively, in two cases (UPN 2 and 8) , and because of toxicity in the other two patients ( UPN 7 and 10) .
Of the four patients who completed all five treatment phases, two experienced severe extra-hematological toxicity (UPN 4 and 6) , which was fatal in one (UPN 6).
At the last evaluation, the two patients (20%) with early relapsing NHL were alive in CR 18 and 20 months after the end of the treatment, whereas the eight patients with refractory NHL had died of disease progression (n ϭ 4), disease relapse (n ϭ 3) or toxicity (n ϭ 1).
Discussion
In this pilot study, sequential HDC with repeated PBSC support was assessed in early relapsing or refractory NHL. Early and/or severe TM occurred in three of the 10 patients included. This frequent and unexpected endothelial toxicity led to early closure of the study. TM has previously been described after allogeneic hematopoietic stem cell transplantation with highly variable incidence rates (3-71%). Risk factors have been identified and include mainly a conditioning regimen with total body irradiation (TBI), CMV infection and cyclosporine therapy. 15, 16 TM is much less frequently observed after autologous stem cell transplantation with incidence rates ranging from 2.6% to 6.8% in large studies, and the cases reported usually occurred several months after the procedure. 16, 17 Survival remained poor in patients who developed TM after stem cell transplantation and especially when TM occurred early and was associated with a high LDH level, a high percentage of fragmented red cells and a low platelet count. 15, 17 TM has occasionally been reported to be associated with a variety of manifestations, including intra-alveolar hemorrhage, 18 veno-occlusive disease, 15 and hemorrhagic cystitis. 15 TM observed after HDC appear to be related to early endothelial cell injury resulting in failure of various organs, which is unusual in classic TM. This assumption is supported by a study in which the underlying mechanisms of HDC-related TM are supposedly different from those recently described in classic TM, which seem to mainly include a deficient von Willebrand factor-cleaving protease.
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Among the three cases of TM observed in our study, two occurred within the first month post treatment, ie very early. The clinical presentation was severe and included renal failure in two patients (that was irreversible in one), cardiac failure in two patients and hemorrhagic cystitis in one patient. Moreover, in two cases, TM was preceded by pneumonitis. Interestingly, pulmonary injury preceding the onset of TM has already been reported after HDC followed by autologous stem cell transplantation. In those patients TM developed within 2 months of the diagnosis of pneumonitis. 17 The cardiac abnormalities observed in our patients were unexpected since all these patients had normal prestudy heart scans. The concomitant onset of TM and cardiac dysfunction suggests that TM could play a role in heart failure. If myocardial microvascular thrombosis and hemorrhage are commonly seen at autopsy, clinical cardiac manifestations remain a rare event in classic TM. 19, 20 The main manifestations involve the conduction system with a risk of sudden death. 21 Myocardial failure and non-bacterial thrombotic endocarditis have also been described. [22] [23] [24] The reasons for the high incidence of TM observed in our study are unclear. None of the cytotoxics used in our 535 Table 2 Outcome after phases III to V See text for case report. PD ϭ progressive disease; PR ϭ partial remission; CR ϭ complete remission; HDC ϭ high-dose chemotherapy; PBSC ϭ peripheral blood stem cell; DOD ϭ died of disease.
protocol have been reported to induce TM when used as single agents. Furthermore, to our knowledge, no case of TM has been described in previous studies of multiple cycles of moderately escalated chemotherapy with PBSC support. [4] [5] [6] [7] [8] [9] By contrast, in other studies in which very highdose chemotherapy was administered over a short time schedule, a pattern of endothelial toxicity, reminiscent of that observed in our study, has been described in some instances. In the study by Rodenhuis et al, 25 two of the seven patients who completed the protocol without dose reduction experienced TM, which was fatal to one of them, and another patient died of veno-occlusive disease. Treatment consisted of cyclophosphamide, thiotepa and carboplatin (CTC) administered at cumulative doses of 6000 mg/m 2 , 460 mg/m 2 and 1600 mg/m 2 , respectively, in three cycles every 5 weeks. Although overt TM was not described in the clinical study reported by Ayash et al 26 that included high-dose melphalan followed by a CTC-like regimen, two of the 20 patients sustained cardiac failure and two others developed veno-occlusive disease. In the study by Pittman et al 27 the only two patients who completed the entire schedule died of early fatal pneumonitis. The first HDC regimen consisted of cyclophosphamide 5625 mg/m 2 , cisplatinum 165 mg/m 2 and carmustine 600 mg/m 2 , and the second HDC regimen included 180 mg/m 2 of melphalan and 900 mg/m 2 of etoposide. All these findings suggest that TM may be a new doselimiting toxicity of high-dose sequential chemotherapy with repeated PBSC transplantation and that the dose intensity and timing of our salvage program played a critical role in the occurrence of endothelial cell damage.
Finally, firm conclusions could not be drawn concerning the efficacy of this program, given the limited number of Bone Marrow Transplantation patients. However, in our hands, sequential HDC did not overcome tumor cell resistance in NHL patients refractory to first-line therapy. These results are consistent with a recent large German series which did not achieve long-term survival in patients with refractory NHL treated with modern second-line chemotherapy, not even in patients in whom high-dose chemotherapy with bone marrow or PBSC support was undertaken. 28 
